GOVX Stock UPDATES Geovax Labs Inc (GOVX) 0.2300 09/10/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Geovax Labs Inc (GOVX) 0.2300 $GOVX

GeoVax's Chief Scientific Officer Featured as Lecturer at American Society for Microbiology Conference
eTeligis - Thu Sep 04, 9:50AM CDT
ATLANTA, GA, United States, via ETELIGIS INC., 09/04/2014 - - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing HIV/AIDS vaccines, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., presented a virtual lecture entitled "Working Towards an HIV Vaccine," on August 29, 2014 at the African Center for Integrated Laboratory Training in Sandringham, South Africa, sponsored by the American Society for Microbiology.

GeoVax to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
ACCESSWIRE - Wed Sep 03, 8:17AM CDT
ATLANTA, GA / ACCESSWIRE / September 3, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing HIV/AIDS vaccines, today announced that it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City. Robert McNally, Ph.D., President and CEO of GeoVax, will deliver the Company presentation to conference attendees on Tuesday, September 9 at 3:20 pm in the Adams Salon at the New York Palace Hotel. Dr. McNally will be joined at the conference by Mark Reynolds, GeoVax's CFO.

GeoVax Reports 2014 Second Quarter Financial Results and Provides Corporate Update
ACCESSWIRE - Thu Aug 07, 8:18AM CDT
ATLANTA, GA / ACCESSWIRE / August 7, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced its financial results for the three and six months ended June 30, 2014 and provided a clinical development update.

GeoVax Announces Clinical Development License Agreement with Valneva SE
ACCESSWIRE - Wed Aug 06, 7:15AM CDT
Use of Valneva's EB66(R) Cell Line to Aid in Development of Commercial-Scale Manufacturing Process for GeoVax's HIV/AIDS Vaccine

VALNEVA enters into clinical development license agreement with GeoVax
M2 - Wed Aug 06, 5:32AM CDT
Biotechnology company Valneva SE announced on Wednesday that it has executed a clinical development license agreement to develop MVA-based vaccines in its EB66 vaccine production cell line.

GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health
ACCESSWIRE - Wed Jul 16, 8:17AM CDT
Atlanta, GA / ACCESSWIRE / July 16, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced today it has received a Notice of Award from the U.S. National Institutes of Health for a Small Business Innovative Research (SBIR) grant entitled "Enhancing Protective Antibody Responses for a GM-CSF Adjuvanted HIV Vaccine." The grant award of approximately $290,000 is for the second year of a two-year project period.

Smallpox - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndtlnz/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - GeoVax Labs, Inc. - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - NanoBio Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/ndtlnz/smallpox

GeoVax Announces Publication of Repeat Challenge Preclinical Trial in the Journal of Virology
Marketwire - Wed Mar 19, 10:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced today the publication of the results of a study in which non-human primates vaccinated with simian prototypes of its HIV vaccine resisted up to 41 rectal exposures to simian immunodeficiency virus (SIV). The article, titled "Local Control of Repeated Rectal Challenges in DNA/MVA Vaccinated Macaques Protected Against a 1st Series of SIV Challenges" was published on-line in the Journal of Virology. An abstract of the article can be located at http://www.ncbi.nlm.nih.gov/pubmed/24574408. The print version will be available in May.

GeoVax Labs Reports 2013 Financial Results and Provides Corporate Update
Marketwire - Wed Mar 05, 7:15AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing innovative, patented HIV/AIDS vaccines, today announced its financial results for the year ended December 31, 2013 and provided the following corporate update.

GeoVax Presents at the Phacilitate Vaccine Forum 2014
Marketwire - Tue Jan 28, 12:00PM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today that its Chief Scientific Officer, Dr. Harriet Robinson, presented information on the selection of antigens and antigen combinations for the elicitation of protective antibody responses for HIV at the Phacilitate Vaccine Forum 2014 on January 27, 2014 in Washington, DC.

GeoVax Announces Publication of Phase 2a Clinical Trial in The Journal of Infectious Diseases
Marketwire - Thu Jan 23, 9:00AM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today the publication of the results of Phase 2a clinical testing of its JS7/MVA62B AIDS vaccine, GOVX-B11. The article, titled "Specificity and Six-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles" was published on-line in The Journal of Infectious Diseases. An abstract of the article can be located at http://www.ncbi.nlm.nih.gov/pubmed/24403557.

GeoVax Announces Preliminary Top-Line Results for Phase 1 Therapeutic Vaccine Trial in HIV-Infected Patients
Marketwire - Mon Jan 13, 7:01AM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today preliminary top-line results from GV-TH-01, a Phase 1 clinical trial investigating the ability of the Company's GOVX-B11 vaccine to control HIV infections in patients who initiated antiretroviral drug treatment within 18 months of seroconversion. The Company expects to release additional results from this trial as final analyses are completed, and in conjunction with scientific presentations and publications.

Immunomedics (IMMU) Jumps: Stock Adds 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 8:25AM CST
Immunomedics was a big mover last session, with shares rising over 10%.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 466

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 223

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 335

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 129

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 246

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading

Top 5 Most Recently Viewed Articles

Geotab's Vision for Addressing Youth Unemployment Through Internships

Updated Category News Views 169

Geotab's Commitment to Future Workforce Development As Geotab Inc. celebrates its remarkable 25th anniversary, the company is taking bold steps to enhance internship opportunities for young graduates entering an increasingly competitive job market. With youth unemployment rates rising in North America, organizations like Geotab are not only addressing a pressing social...

Continue Reading
Joaquín de Valenzuela Joins nCino as EMEA Managing Director

Updated Category News Views 90

Joaquín de Valenzuela Takes the Helm at nCino for EMEA nCino, Inc. (NASDAQ: NCNO), a leader in intelligent banking solutions, is proud to announce the appointment of Joaquín de Valenzuela as the Managing Director for the EMEA region. This significant hire underscores the company's dedication to bolstering its growth trajectory and expanding its influence across the...

Continue Reading
Aya Gold & Silver Unveils Stunning Silver Drilling Results

Updated Category News Views 123

Aya Gold & Silver Reports New Silver Drilling Success Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) is excited to share outstanding silver drill results from its ongoing exploration at the Zgounder Silver Mine. The results not only highlight high-quality silver finds but also identify several promising new targets in the Zgounder Regional area. Drilling Highlights and...

Continue Reading
Nvidia's Deep Roots in China's Tech Landscape Drive AI Success

Updated Category News Views 278

Nvidia's Deep Roots in China's Tech Landscape Drive AI Success Nvidia Corp. CEO Jensen Huang recently highlighted the significant impact of China’s technology ecosystem on Nvidia’s growth during a keynote address at a major university event. His reflections underline a robust relationship spanning over 25 years, which has been pivotal in shaping Nvidia into a leading...

Continue Reading
Aalberts N.V. Achieves Strategic Growth Despite Market Challenges

Updated Category News Views 314

Aalberts N.V. Reports First Quarter Results In the latest financial report, Aalberts N.V. showcased its first quarter outcomes, revealing revenues of EUR 778.3 million. This figure marks a 3.3% decline in organic revenue compared to the same period last year, pointing to ongoing challenges within the market. Operational Performance and Margin Insights The company's EBITA...

Continue Reading